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Abstract
Phosphorylation is considered a key event in the signalling and regulation of the μ opioid receptor
(MOPr). Here we used mass spectroscopy to determine the phosphorylation status of the Cterminal tail of the rat MOPr expressed in HEK-293 cells. Under basal conditions, MOPr is
phosphorylated on Ser363 and Thr370, while in the presence of morphine or [D-Ala2, NMe-Phe4,
Gly-ol5]-enkephalin (DAMGO), the COOH-terminus is phosphorylated at three additional
residues, Ser356, Thr357, and Ser375. Using N-terminal Glutathione S Transferase (GST) fusion
proteins of the cytoplasmic, C-terminal tail of MOPr and point mutations of the same, we show
that, in vitro, purified G protein-coupled receptor kinase 2 (GRK2) phosphorylates Ser375, PKC
phosphorylates Ser363 whilst CaMKII phosphorylates Thr370. Phosphorylation of the GST fusion
protein of the C-terminal tail of MOPr enhanced its ability to bind arrestin-2 and -3. Hence, our
study identifies both the basal and agonist-stimulated phospho-acceptor sites in the C-terminal tail
of MOPr, and suggests that the receptor is subject to phosphorylation and hence regulation by
multiple protein kinases.

NIH-PA Author Manuscript

Keywords
μ opioid receptor; mass spectrometry; phosphorylation; kinases; arrestins; desensitization

Introduction
Phosphorylation of MOPr has been implicated in the desensitization and trafficking of the
receptor, as well as in the development of opioid tolerance in the intact organism (Johnson et
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Note: The LC-MS/MS data described here was first presented as an abstract at the July 2010 INRC in Malmo, Sweden (http://
www.inrcworld.org/2010/INRC%20program&abstract%20Final.pdf) page 99.
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al. 2005; Dang and Christie 2012; Kelly et al. 2008; Kelly 2011). The identity of
phosphorylated amino acids in the intracellular regions of MOPr is therefore of considerable
interest and importance. Using a [32P]orthophosphate metabolic prelabelling approach, in
conjunction with site-directed mutagenesis, previous studies have identified amino acids in
MOPr that are phosphorylated under basal conditions or in response to opioid agonist (Deng
et al. 2000; El Kouhen et al. 2001; Wang et al. 2002; Schulz et al. 2004; Ozsoy et al. 2005;
Wang et al. 2007; Chu et al. 2008). However there remains disagreement as to the identity
of phosphorylated residues, as well as the role of such residues in the regulation of MOPr
(Pak et al. 1997; Burd et al. 1998; Deng et al. 2000; El Kouhen et al. 2001; Wang et al.
2002; Schulz et al. 2004; Johnson et al. 2005; Ozsoy et al. 2005; Wang et al. 2007; Chu et
al. 2008). This may in part be due to the previous reliance on the use of MOPr point
mutations to confirm phosphorylation data. Such mutations might influence receptor
function in ways that are not related to the phosphorylation of that particular residue (Kim et
al. 2005). A better approach would be the direct identification of phosphorylated residues in
the receptor by mass spectrometry. This has been achieved for some G protein-coupled
receptors (GPCRs) including the β2-adrenoceptor (Trester-Zedlitz et al. 2005; Nobles et al.
2011), the V2 vasopressin receptor (Wu et al. 2008) and the CXCR4 receptor (Busillo et al.
2010). In the case of opioid receptors, mass spectrometry has been employed to sequence
the purified MOPr and KOPr (Christoffers et al. 2003; Wannemacher et al. 2008). Very
recently it has also been applied to study the phosphorylation sites of the C-terminal tail of
MOPr (Lau et al. 2011; Feng et al. 2011; Moulédous et al. 2012).
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Apart from the identification of phospho-acceptor sites, the kinases that mediate these
phosporylatyion events are generally not known. However G protein-coupled receptor
kinases have been implicated in the phosphorylation of Ser375 (Schulz et al. 2004). Here we
use Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) to identify
phosphorylated amino acids in the cytoplasmic, C-terminal tail of MOPr. We find that this
region of MOPr is phosphorylated on multiple residues both under basal conditions and
upon stimulation by agonist. Furthermore, using GST fusion proteins of the C-terminal tail
of the receptor we identify, in vitro, possible sites for phosphorylation by both GRK2 and
second messenger-dependent protein kinases. Finally, we demonstrate that phosphorylation
of the C-terminal tail of MOPr increases its ability to interact with arrestins.
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Materials and Methods
Cell culture
HEK293 cells stably expressing MOPr (~0.5 pmol/mg membrane protein) tagged at the NH2
terminus with hemagglutinin (HA) were grown in Dulbecco's Modified Eagle's medium
(Invitrogen, Paisley, UK) supplemented with 10% foetal calf serum, 200 μg/ml geneticin
(PAA, Pasching, Austria), 10 U/ml penicillin and 10 μg/ml streptomycin. For experimental
purposes, cells were grown to approximately 90% confluence and incubated with 10 μM
DAMGO, 30 μM morphine or with no drug for 10 min, washed twice in ice-cold phosphate
buffered saline and scraped into lysis buffer (20 mM Tris/HCl pH7.4, 140 mM NaCl, 1 mM
EDTA containing protease inhibitors (Complete; Roche Products, Welwyn Garden City,
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UK) and phosphatase inhibitors (PhosStop; Roche Products)). Unless otherwise stated, all
drugs, chemicals and kits were obtained from Sigma-Aldrich (Poole, UK).
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Affinity purification of HA-tagged MOPr and tryptic digestion
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A flowchart outlining the methodology is shown in Fig. 1A. Cells from 12 × 150 cm2 flasks
were scraped into 25 ml lysis buffer and lysed with a Polytron homogeniser. Nuclei and cell
debris were removed by centrifugation at 3,000 g for 5 min, and the supernatant was diluted
to 50 ml with lysis buffer and subjected to centrifugation at 40,000 g for 1 h. The resultant
membrane pellet was washed with lysis buffer and then dissolved in 5 ml lysis buffer
containing 1% of the detergent NP40. Insoluble material was removed by centrifugation and
the supernatant diluted 2-fold with 20 mM Tris/HCl pH 7.4, 140 mM NaCl. MOPr was
immunoprecipitated by mixing with agarose beads coupled to anti-HA antibody (200 μl)
(Roche Products) at 4°C overnight. Beads were then washed three times with 20 mM
Tris/HCl pH7.4, 140 mM NaCl, 0.5% NP40. Bound proteins were eluted into SDS sample
buffer and subjected to SDS-PAGE. The gel was stained with colloidal Coomassie blue and
the band corresponding to MOPr (~80kD) was excised. (For the purposes of photography
one gel was stained using the ProteoSilver™ Plus Silver Stain kit (Bio-Rad laboratories,
Hemel Hempstead, UK) according to the supplier's instructions; see Fig. 1B). The gel slice
was washed three times for 15 min with 100 mM ammonium bicarbonate. Reduction and
alkylation of cysteine residues was performed by incubation of the gel slice in 50 mM
ammonium bicarbonate containing 10 mM dithiothreitol at 60°C for 30 min followed by
incubation in 50 mM ammonium bicarbonate containing 100 mM iodoacetamide for 30 min
in the dark. Gel slices were washed 3 times for 5 min with 50 mM ammonium bicarbonate
containing 50% acetonitrile and incubated overnight at 37°C in 50 mM ammonium
bicarbonate containing 1 μg sequencing grade trypsin (Promega, Southampton, UK). The
solvent was removed in a under vacuum in a centrifugal concentrator and the peptides
redissolved in 0.1% triflouroacetic acid.
LC-MS/MS
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LC-MS/MS was carried out upon each sample using an LTQ (Linear Trap Quadrupole)
Orbitrap mass spectrometer by the Protein and Nucleic Acid Chemistry Laboratory at the
University of Leicester. Briefly, peptides resulting from in-gel digestion were loaded at high
flow rate onto a reverse-phase trapping column (0.3 mm i.d. × 1 mm), containing 5 μm C18
300 Å Acclaim PepMap media (Dionex, Camberley, UK) and eluted through a reversephase capillary column (75 μm i.d. × 150 mm) containing Symmetry C18 100 Å media
(Waters, Elstree, UK). The output from the column was sprayed directly into the nanospray
ion source of the LTQ Orbitrap mass spectrometer. The resulting spectra were analysed
against the UniProtKB/SwissProt database using MASCOT software (Matrix Science Ltd.,
London, UK) with peptide tolerance set to 5 ppm and the MS/MS tolerance set to 0.6
Daltons. Fixed modifications were set as carbamidomethyl cysteine with variable
modifications of phosphoserine, phosphothreonine, phosphotyrosine and oxidised
methionine. The enzyme was set to Trypsin/P and up to 2 missed cleavages were allowed.
Peptides with a MASCOT score greater than 20 and where the probability (P) that the
observed match was a random event was <0.05 were included in the analysis. The spectra of
peptides reported as being phosphorylated were interrogated manually to confirm the precise
J Neurochem. Author manuscript; available in PMC 2014 November 10.

Chen et al.

Page 4

sites of phosphorylation. For each condition (i.e. plus DAMGO or morphine) the experiment
was conducted 3 times and the results presented as a summary in Fig. 2.
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GST-fusion protein expression and purification
The Glutathione-S-transferase (GST) fusion proteins, including GST-rat MOPr-2nd
intracellular loop (GST-2IL), GST-rat MOPr-3rd intracellular loop (GST-3IL), and GST-rat
MOPr C-terminal tail (GST-CT) were expressed in the pGEX-4T-1 vector. The sequences
for MOPr-2IL, -3IL, and -CT were, respectively,
S162VDRYIAVCHPVKALDFRTPRNAK185;
L257RLKSVRMLSGSKEKDRNLRRITRMV282;
N328SCLNPVLYAFLDENFKRCFREFCIPTSSTIEQQNSTRVRQNTREHPSTANTVDRT
NHQLENLEAETAPLP398. To generate a specific amino acid mutation in the GST fusion
protein of MOPr-CT, the GeneTailor™ Site-Directed Mutagenesis System kit (Invitrogen,
Paisley UK) was used. All the recombinant pGEX-4T-1 plasmids were transformed into
BL21 (DE3) E. coli competent cells. Bacteria were grown in LB broth and protein
expression induced by 0.5 mM isopropyl-beta-D-thiogalactopyranoside (IPTG; Apollo
Scientific, Stockport UK) at 15°C overnight.
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Bacterial cells were harvested by centrifugation at 5,040 g and 4°C for 15 min. The cell
pellets were then resuspended in a lysis buffer (20 mM HEPES pH 7.4, 100 mM KCl)
supplemented with 1 mM EDTA, 20 mM β-mercaptoethanol, 1 mM dithiothreitol, and
protease inhibitors (0.5 mM benzamidine hydrochloride, 4 μg/ml leupeptin, and 4 μg/ml
pepstatin), followed by 4 periods of sonication (30 sec each on dial 3, Misonix sonicator
XL2020) to disrupt the cells. Triton-X 100 (1 % final concentration) was added to sonicated
cells, followed by a further incubation at 4°C with gentle shaking to ensure efficient cell
lysis. The unwanted pellets were removed by centrifugation of the lysate at 43,100 g at 4°C
for 20 min. The supernatant containing the GST-fusion proteins was further incubated at
4°C overnight, with a 50% slurry of glutathione sepharose 4B beads (GE Healthcare,
Chalfont St Giles, UK), which had been prewashed and resuspended in lysis buffer. The
GST-fusion protein-bound beads were then collected by a brief spin in a microcentrifuge,
washed twice in lysis buffer, resuspended in 1 volume of lysis buffer and 2 volumes of
glycerol and stored at -20°C.
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Kinase-induced phosphorylation of GST fusion proteins
CaMKII requires activation by autophosphorylation before being used in the
phosphorylation reaction. The activation reaction contained 1 μl (500 units) of CaMKII
(New England BioLabs, Hitchin, UK) in the presence of 20 μM ATP, 1 mM calcium
chloride, and 0.075 μM calmodulin in a final volume of 10 μl. Activation of the CaMKII
mixture was performed at 30°C for 10 min to enable the autophosphorylation and hence
activation of CaMKII.
The GST-fusion proteins immobilized on glutathione sepharose beads were washed and
resuspended in assay buffer (20 mM HEPES pH7.4, 1 mM dithiothreitol) up to a final
volume of 10 μl. The CaMKII-induced phosphorylation was initiated by incubating 5 μl of
sample proteins in the presence of 10 μl of pre-activated CaMKII mixture, 5 μl of ATP
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mixture (0.02 mM ATP, 10 mM MgCl2), and 2.8 μCi [γ-32P]ATP to a final volume of 25 μl.
The final concentration of CaMKII was 100 nM. The phosphorylation reaction was allowed
to proceed at 30°C for 15 min.
For PKC-induced phosphorylation, 5 μl washed beads were incubated with PKC
(Calbiochem, Nottingham Uk, final concentration 100 nM), 5 μl ATP mixture, and 2.8 μCi
[γ-32P]ATP, in a final volume of 25 μl at 30°C for 15 min.
For GRK2-induced phosphorylation, the washed beads were resuspended in 20 mM HEPES
pH7.4, 1 mM dithiothreitol, and 1 mM EDTA. Reaction mixtures contained 5 μl sample
protein, 100 nM GRK2 , 5 μl of ATP mixture, and 2.8 μCi of [γ-32P]ATP in a total volume
of 25 μl and were incubated at 30°C for 15 min.
The kinase-induced phosphorylation reactions were stopped by the addition of 5 x SDS
sample buffer to the reactions and heating at 100°C for 5 min. The proteins were then
resolved by 12 % SDS-PAGE. The protein bands were visualized by staining with
Coomassie blue; the gels with phosphorylated bands were visualised by autoradiography.
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The software Image J (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2009) was used to quantify the density of
the phosphorylated bands on the autoradiograph, and the protein bands on the Coomassie
blue-stained gel. The level of phosphorylation was quantified by normalizing the density of
phosphorylated bands to the density of their corresponding protein bands, which represented
the amount of protein used in each experiment. If no phosphorylated band was evident on
the autoradiograph, the position corresponding to the protein band on the gel was identified
and used in quantification. In the assays to identify phosphorylation sites for each kinase,
after quantification as above, the phosphorylation level of each fusion protein containing the
mutant MOPr sequence was compared to the phosphorylation level of the corresponding
fusion protein containing WT sequence (taken as 100%).
Arrestin interaction with GST fusion proteins
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Arrestin-2 and -3 were purified as previously described (Gurevich and Benovic, 2000; Zhan
et al., 2011). GST fusion proteins on sepharose beads were made up to a total volume of 500
μl in assay buffer (20 mM Tris, pH 7.5, 200 mM NaCl), and different amounts of purified
arrestin-2 or arrestin-3 (final concentrations of 40, 200, 500, 1000, 1500 and 2000 ng/ml;
2000 ng/ml is approximately equal to 44 nM) were added, and mixed by rotation at 4°C
different lengths of time (30 min, 1 h or 2.5 h). Following the incubation, beads were
recovered by centrifugation and washed three times with assay buffer and analysed by SDSPAGE. For Western blotting, proteins were transferred onto polyvinylidene fluoride
membrane and the membrane stained with Ponceau S to determine the amount of GSTfusion protein present. Following this the amount of arrestin-2 or -3 bound was determined
using a rabbit polyclonal pan-arrestin antibody (1:3,000 dilution; Abcam, Cambridge, UK)
and a donkey anti-rabbit IgG horseradish peroxidase (HRP)-linked secondary antibody
(1:12,000 dilution; GE Healthcare). Amounts of GST-fusion protein and arrestin-2 or -3
present on membranes, were quantified using Image J.
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Statistics
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An unpaired t test was further used to compare the phosphorylation of GST fusion proteins
to that of GST alone. A one-sample t test was used to compare the phosphorylation of
mutants to the wild type GST fusion proteins, and to compare the binding of arrestins to
different GST fusion proteins, and to phosphorylated and non-phosphorylated fusion
proteins. Differences were regarded as significant when p < 0.05.

Results
Identification of phosphorylation sites in the C-terminal tail of MOPr in intact cells
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When MOPr was affinity purified from HEK293 cells and subjected to SDS-PAGE, a band
at the expected molecular weight for the rat MOPr (~ 80kDa) was observed (Fig. 1B). Mass
spectrometric analysis of the purified MOPr identifed a series of peptide derived from the
intracellular C-terminal tail. MS/MS sequencing of these peptides provided coverage of the
entire C-terminal tail and identified a number of phospho-acceptor sites (Fig. 2 and see
Supplementary Fig. 1). To assess the selective phosphorylation on the C-terminal tail of
MOPr under basal and agonist-stimulated conditions, the HEK293 cells stably expressing
HA-MOPr were incubated in the absence or presence of saturating concentrations of
DAMGO (10 μM) or morphine (30 μM) for 10 min. Under basal conditions, Ser363 and
Thr370 were found to be phosphorylated. In replicate 1, a singly phosphorylated peptide
corresponding to the sequence around Ser363 was present but it was not possible to
distinguish whether it was phosphorylated on Ser363 or Thr364. However, the MS/MS
spectra generated in replicate 2 clearly showed the site to be Ser363.
On stimulation of the receptor with either morphine or DAMGO, these residues were still
phosphorylated and three additional phosphorylation sites were found on Ser356, Thr357 and
Ser375 (Fig. 2A). A summary of phosphorylated residues in the C-terminal tail of MOPr is
shown in Fig. 2B.
GRK2 and second messenger-dependent protein kinases phosphorylate distinct residues
on the C-terminal tail of MOPr expressed as a GST fusion protein
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We investigated the in vitro ability of CaMKII, PKC and GRK2 to phosphorylate GST
fusion proteins of the MOPr C-terminal tail in vitro using [γ-32P]-ATP incorporation. In
preliminary experiments, we tested the ability of these kinases to phosphorylate the 2nd and
3rd intracellular loops of MOPr in comparison to the C-terminal tail. All three kinases were
able to phosphorylate intracellular regions of MOPr expressed as GST-fusion proteins,
whilst GST alone was not phosphorylated by any of the kinases (Fig. 3). Notably the
GST-3IL was markedly phosphorylated by each kinase, whilst phosphorylation of the GSTCT was also observed with the kinases, with GRK2 being particularly effective in
phosphorylating this region (Fig. 3). The specificity of CaMKII- and PKC-induced
phosphorylation was confirmed with the selective inhibitors KN93 (10 μM) or GF109203X
(10 μM), respectively (Supplementary Fig. 2A and B).
Further experiments were directed at identifying the phosphorylated residues in the COOH
terminal tail of MOPr, since this region is mostly associated with receptor regulation (Kelly
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2011). Point mutations were introduced into GST fusion proteins at residues likely to
undergo phosphorylation. These experiments (Fig. 4) indicated clearly that, under these in
vitro conditions, Thr370 is the main substrate for CaMKII phosphorylation, Ser363 the main
substrate for PKC phosphorylation, and Ser375 the main substrate for GRK2
phosphorylation. In addition, CaMKII-induced phosphorylation of the Ser363Ala mutant was
moderately but significantly increased, whilst PKC-induced phosphorylation of the
Ser356Ala/Ser357Ala double mutant was moderately but significantly reduced.
Arrestin-2 and -3 binding to the intracellular regions of MOPr
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The ability of arrestin-2 and -3 to bind to GST fusion proteins of the intracellular regions of
MOPr in vitro was also examined. In preliminary experiments, the interaction of purified
arrestin-2 or -3 with GST-CT was shown to be concentration- and time-dependent
(Supplementary Fig. 3 and 4), the latter being similar to that previously reported for arrestin
interaction with other GPCRs (Gurevich et al., 1995). The ability of purified arrestins to
interact with the intracellular regions of MOPr was then tested. Interestingly, whereas
arrestin-3 bound avidly to GST-2IL and GST-3IL as well as GST-CT (Fig. 5C and D),
arrestin-2 interacted much more readily with the C-terminal tail fusion protein than with
those of the intracellular loops (Fig. 5A and B). We also tested the ability of GST-CT to
interact with arrestins following phosphorylation by GRK2, PKC or CaMKII. The fusion
protein was phosphorylated by the kinases as described above. Following this in vitro
phosphorylation, the GST fusion protein was incubated with arrestin-2 or arrestin-3. Under
these conditions phosphorylation by each of the three kinases enhanced the ability of
arrestin-2 and -3 to bind to the GST fusion protein of MOPr, with the greatest increase in
interaction being seen following GRK2 phosphorylation (Fig. 6).

Discussion
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These results provide unequivocal identification of phosphorylated residues in the Cterminal tail of MOPr expressed in HEK293 cells. The key findings of this work are that in
these cells MOPr is phosphorylated in the absence of agonist; that DAMGO- and morphineinduced phosphorylation involves multiple but similar residues in the C-terminal tail; that in
vitro three kinases, CaMKII, PKC, and GRK2 phosphorylate distinct residues in the Cterminal tail of MOPr; that in vitro arrestin-2 and -3 interact with the C-terminal tail of
MOPr, and that this interaction is increased following kinase-induced phosphorylation of the
protein.
A cluster of four amino acids (Thr354Ser355Ser356Thr357; refer to Fig. 2B) in the C-terminal
tail of MOPr was previously reported to mediate agonist-induced desensitization of receptor
responsiveness (Wang 2000), with Ser355 and Thr357 in particular being identified as likely
phosphoacceptor sites (Wang et al., 2002). However others have reported that this cluster is
not involved in either agonist-induced phosphorylation or desensitization of MOPr (Deng et
al. 2000; El Kouhen et al. 2001). Here we confirm that Thr357 is phosphorylated in response
to agonist and also identify Ser356 as a phosphorylated residue, rather than Ser355 as
suggested previously (Wang et al. 2002). Furthermore our in vitro 32P-incorporation
experiments identify PKC as a possible kinase for one or both of these sites, however it is
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also possible that mutation on this Ser/Thr pair instead affects the PKC-induced
phosphorylation of the nearby Ser363.
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On the basis of point mutations, Ser363 and Thr370 in the C-terminal tail of MOPr were
suggested to be phosphoacceptor sites (El Kouhen et al. 2001). The present results using
mass spectrometry confirm this and, in addition, demonstrate that these residues can be
phosphorylated in the absence of agonist treatment. However this does not preclude the
possibility that these residues are further phosphorylated in the presence of agonist. A recent
study (Doll et al. 2011) with antiphosphoreceptor antibodies also identifies Ser363 and
Thr370 as phosphoacceptor residues, although these authors concluded that Thr370 was only
phosphorylated in response to DAMGO, and not with morphine or under basal conditions.
Another recent study (Feng et al. 2011) indicated that phorbol ester-induced desensitization
of MOPr is mediated by PKC-dependent phosphorylation of Ser363. Interestingly using the
in vitro GST fusion protein 32P-incorporation assay, we now show that Ser363 and Thr370
are preferentially phosphorylated by PKC and CaMKII, respectively. MOPr has been
suggested to be pre-phosphorylated by PKC (Johnson et al. 2006), which may underlie the
ability of morphine to induce MOPr desensitization in neurones (Bailey et al. 2009a; Bailey
et al. 2009b). In addition CaMKII activation has been implicated in morphine tolerance
(Mestek et al. 1995; Koch et al. 1997; Fan et al. 1999). It remains to be seen whether or not
such effects are indeed due to phosphorylation of these residues on MOPr by these second
messenger-dependent kinases, or instead due to phosphorylation of other cellular substrates
that contribute to morphine tolerance.
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An anti-phosphoserine375 antibody has been developed and its use has already demonstrated
that Ser375 is phosphorylated in an agonist-dependent manner (Schulz et al. 2004; Chu et al.
2008; McPherson et al. 2010). We confirm here that this residue is indeed phosphorylated in
response to agonist. Mutation of this Ser375 has been reported to inhibit agonist-induced
desensitization (Ozsoy et al. 2005; Chu et al. 2008) and internalization of MOPr (El Kouhen
et al. 2001), although in another study this mutation inhibited morphine- but not DAMGOinduced desensitization (Schulz et al. 2004), whilst in yet other studies MOPr constructs
with multiple mutations including of Ser375 were still able to undergo agonist-induced
desensitization similar to the wild type MOPr (Pak et al. 1997; Deng et al. 2000). Clearly
the precise role of Ser375 and its phosphorylation in MOPr function requires further study.
On the other hand, Ser375 has been suggested to be the phosphorylation site for GRK2
(Schulz et al., 2004) and in vitro phosphorylation data from the present study suggests that
GRK2 is the likely kinase involved, although other GRKs may also be involved in vivo. In
addition the ability of GRK2 to phosphorylate the agonist-occupied receptor is likely to be
much greater than its ability to phosphorylate receptor fusion protein sequences (Benovic et
al., 1990). A recent study identifies further phosphoacceptor sites in a cluster (S375TANT)
around Ser375 including Thr376 and Thr379 (Lau et al. 2011; Moulédous et al. 2012);
phosphorylation of these residues was associated with arrestin interaction with MOPr (Lau
et al. 2011). However with regard to the data in the present study, it will be interesting to
assess the effect of mutating the residues whose phosphorylation is agonist-dependent
(Ser356, Thr357 and Ser375), on agonist-induced desensitization and trafficking of MOPr.
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On the basis of mutation data Thr394 has been identified in more than one study as a possible
phosphoacceptor site (Pak et al. 1997; Deng et al. 2000). We were unable to detect
phosphorylation of this residue, strongly suggesting that Thr394 is not phosphorylated.
However with our present data we cannot absolutely rule out Thr394 as a phosphoacceptor
site since it remains theoretically possible that the relevant phosphopeptide was missed in
our analysis, but it is noteworthy that phosphorylation in the distal section of the COOHterminus of MOPr was not detected in other recent studies (Lau et al. 2011; Moulédous et
al. 2012). Mutation of Thr394 has also been reported to markedly reduce agonist-induced
desensitization and down regulation of MOPr (Pak et al. 1997; Deng et al. 2000), whilst a
mutant MOPr with Thr394 mutated to alanine displays increased internalization and
resensitization (Wolf et al. 1999). However, if Thr394 is not phosphorylated, then it is
possible that this residue or the region of the COOH-terminus around it has some wider role
in controlling MOPr function, such as a permissive role in kinase recruitment or perhaps this
region of MOPr interacts with scaffolding proteins that are important for appropriate
receptor regulation. The latter is supported by the finding that mutation of three glutamate
residues close to Thr394 also inhibited MOPr desensitization (Pak et al. 1997).
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With regard to the GST-fusion protein phosphorylation data in this study, it should be noted
that the phosphorylation of a peptide by a particular kinase may not always reflect events in
the intact cell. In addition the potential interaction of the C-terminal tail of the intact MOPr
with other intracellular regions of the receptor, or with interacting proteins or even the
membrane itself could influence the nature and extent of phosphorylation. These potential
influences would be absent in the GST-fusion protein experiments. Furthermore, there is the
question of the cellular activation of the three kinases identified as mediating the
phosphorylation of the C-terminal tail. Whilst there is clear evidence that following MOPr
activation, GRK (Doll et al. 2012) and PKC (Chu et al. 2010) are activated, there is less
evidence to implicate CaMKII (Mestek et al. 1995, Sanchez-Blazquez et al. 2008), although
in the intact brain these kinases could be activated by ongoing neuronal activity and
consequent increases in intracellular free Ca2+; such a mechanism would give rise to
heterologous regulation of MOPr. Furthermore the present results report phosphorylation of
MOPr expressed in HEK293 cells, but it is possible that the receptor phosphorylation profile
would be different in another cellular context such as neurones (Tobin et al. 2008; Torrecilla
et al. 2007). Nevertheless it is of interest that morphine-induced desensitization of MOPr in
the locus coeruleus requires ongoing PKC activity (Bailey et al. 2009a; Bailey et al. 2009b),
suggestive of the possibility that basal MOPr phosphorylation also occurs in neurones. It is
also possible that MOPr is phosphorylated at intracellular sites in addition to the C-terminal
tail; for example Thr180 in the third intracellular loop of MOPr has been suggested to be a
GRK phosphorylation site (Celver et al., 2001).
Previous studies have suggested that non-visual arrestins interact poorly if at all with the
intracellular regions of MOPr (Cheng et al. 1998; Cen et al. 2001), although our recent work
indicates that arrestin-3 does associate with intact MOPr in intact cells in an agonistdependent manner (McPherson et al. 2010). In the present study we found a robust
interaction between purified arrestins and GST fusion proteins, with both arrestin-2 and -3
being able to associate with the GST fusion protein of the C-terminal tail of MOPr.
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Interestingly we found that phosphorylation of the GST-CT increased its interaction with
each arrestin. Under the conditions of the assay GRK2 phosphorylation produced the
greatest increase in arrestin association. Whether or not phosphorylation of Ser363 or Thr370
affect arrestin association or MOPr trafficking in intact cells is less clear, but it should be
noted that Ser363 is basally phosphorylated but does not lead to constitutive arrestin
association with the receptor (Zhang et al., 1998; McPherson et al., 2010). Indeed, mutation
of Ser363 actually enhances agonist-induced internalization of MOPr (El Kouhen et al.
2001). On the other hand previous studies have shown that GPCRs normally require
phosphorylation of two or more residues for tight binding of arrestins to occur (Gurevich et
al., 1995; Vishnivetskiy et al., 2007), perhaps explaining the inability of arrestin to associate
with the basally-phosphorylated MOPr in intact cells. Recent work also indicates that
dependency on GPCR phosphorylation versus receptor activation for arrestin association is
receptor subtype-dependent (Gimenez et al. 2012). The present results and those from other
studies (Lowe et al., 2002; Lau et al. 2011; see references in Gurevich and Gurevich, 2006)
suggest that arrestin association with the C-terminal tail of MOPr as well as other GPCRs
has both phosphorylation-dependent and phosphorylation-independent components.

NIH-PA Author Manuscript

In conclusion, we have identified phosphorylated residues in the C-terminal tail of the rat
MOPr stably expressed in HEK293 cells by LC-MS/MS. We have also identified candidate
kinases for the phosphorylation of some of these residues, and show that phosphorylation by
a range of protein kinases can enhance the association of arrestins with MOPr. Together
these findings support the idea that MOPr signalling and regulation can be modulated by
multiple kinase-dependent mechanisms.
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G protein-coupled receptor
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G protein-coupled receptor
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hemagglutinin

LC-MS/MS
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Fig. 1.

(A) Flow diagram of methodology for MOPr purification and preparation for LC-MS/MS.
(B) Gel stained with ProteoSilver™ Plus Silver Stain to demonstrate purity of the MOPr
preparation.

J Neurochem. Author manuscript; available in PMC 2014 November 10.

Chen et al.

Page 15

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Fig. 2.
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Identity of phosphorylated residues in MOPr. (A) MOPr phosphopeptides obtained in the
presence or absence of morphine or DAMGO. Phosphorylated Ser or Thr residues are
denoted by larger red letters. Spectra were analysed against the UniProtKB/SwissProt
database using MASCOT software with peptide tolerance set to 5 ppm and the MS/MS
tolerance set to 0.6 Daltons. The spectra of peptides reported as being phosphorylated were
interrogated manually to confirm the precise sites of phosphorylation. (B) Summary of
phosphorylation sites in the MOPr C-terminal tail. The phosphorylated Ser or Thr residues
(Ser356, Thr357, Ser363, Thr370, and Ser375) are underlined, as is the NPXXY motif, at the
base of the 7th transmembrane domain where the C-terminus begins. The mass spectrometry
experiments described here were carried out three times for each condition. The data
presented is a summary of these experiments and the spectra shown in Supplementary Fig. 1
are representative of the results obtained.
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Fig. 3.

In vitro phosphorylation of intracellular regions of MOPr. GST fusion proteins (GST alone,
GST-2IL, GST-3IL, GST-CT) immobilized on glutathione-Sepharose beads were incubated
with purified CaMKII (preactivated), PKC, or GRK2 in the presence of [γ32P]ATP.
Following SDS-PAGE, kinase-induced phosphorylation was detected by autoradiography
(top panels), whilst the relative amounts of GST-fusion proteins were determined with
Coomassie blue (middle panels). Bar graphs showing quantitation of phosphorylation are
shown (bottom panels). Values are means ± SEM from 3-4 independent experiments in each
case. All three kinases produced significant phosphorylation of the 3rdIL and CT of MOPr
(unpaired t test, *** p < 0.001, ** p < 0.01 compared to GST alone).
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Fig. 4.
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Identification of In vitro phosphorylation sites in the C-terminal tail of MOPr. GST fusion
proteins (wild type and mutant) immobilized on glutathione-Sepharose beads were
incubated with purified CaMKII (preactivated), PKC, or GRK2 in the presence of
[γ32P]ATP. Following SDS-PAGE, kinase-induced phosphorylation was detected by
autoradiography (top panels), whilst the relative amounts of GST-fusion proteins were
determined with Coomassie blue (middle panels). Bar graphs showing quantitation of
phosphorylation relative to wild type (CT) constructs are shown (bottom panels). Values are
means ± SEM from 3-4 independent experiments in each case. CaMKII phosphorylation
was significantly reduced in the Thr370Ala mutant, PKC phosphorylation in the Ser363Ala
mutant, and GRK2 phosphorylation in the Ser375Ala mutant (one sample t test, *** p< 0.001
compared to respective wild type). PKC phosphorylation was also reduced in the
Ser356Ala/Thr357Ala double mutant (* p< 0.01 compared to respective wild type), whilst
CaMKII phosphorylation was increased in the Ser363Ala mutant (* p< 0.01 compared to
respective wild type).
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Fig. 5.
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Arrestin-2 and -3 interaction with GST fusion proteins of the intracellular regions of MOPr.
Purified (A, B) arrestin-2 or (C, D) arrestin-3 (final concentration 500 ng/ml in each case,
approximately 11 nM) was incubated with GST alone or with GST-2IL, GST-3IL or GSTCT. Example blots are shown in (A) and (C), whilst bar graps of data from 3-4 experiments
are shown in (B) and (D). These results are shown as a % of arrestin binding to the GSTCT,
taken as 100%, with error bars representing S.E.M. * p < 0.05 compared to binding of
relevant arrestin to GST-CT, one-sample t test.
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Fig. 6.

NIH-PA Author Manuscript

Phosphorylation increases the interaction of arrestin-2 and -3 with the GST-fusion protein of
the C-terminal tail of MOPr. The GST-CT was subjected to phosphorylation by CaMKII,
PKC, or GRK2 as described in the Methods section and their ability to interact with
arrestin-2 or -3 (final concentration 500 ng/ml in each case, approximately 11 nM) was
compared with that for nonphosphorylated GST-CT. Representative blots of the interaction
of arrestin-2 (A) and arrestin-3 (B) with the non-phosphorylated and GRK2-phosphorylated
GST-CT are shown, as well as (C) a bar graph showing data from at least 4 independent
experiments. In all cases, phosphorylation increased arrestin-2 and arrestin-3 binding to the
GST-CT. These results are shown as a % of arrestin binding to the non-phosphorylated
GST-CT, taken as 100%, with error bars representing S.E.M. * p < 0.05 compared to
binding of relevant arrestin to non-phosphorylated GST-CT (taken in each case as 100%),
one-sample t test.
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